New study to see how well elranatamab works in everyday care for myeloma patients
NCT ID NCT07391761
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand the drug's real-world effectiveness and treatment patterns outside of a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- elranatamab
- What this could lead to
- If successful, this study could confirm that elranatamab is effective outside of clinical trials, helping doctors in Taiwan make better treatment decisions for multiple myeloma.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient differences. It is small (30 patients) and only in Taiwan, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kaohsiung Chang Gung Memorial Hospital
Kachsiung, 833, Taiwan
-
Linkou Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.